echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > RNA therapy is again favored by large pharmaceutical companies. MSD and SGI have reached cooperation one after another

    RNA therapy is again favored by large pharmaceutical companies. MSD and SGI have reached cooperation one after another

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    RNA splicing errors may result in the loss of mRNA expression levels, resulting in a series of neurological diseases including neuroblastoma, ALS, PD, FTD and SMASkystar technology platform of skyhawk is a platform for discovering innovative small molecule drugs targeting RNA, which can be used to discover small molecule compounds, correct RNA splicing errors in the nucleus and restore mRNA expression level by binding with RNA precursors< br / > under the agreement, skyhawk will be responsible for using the skystar technology platform to find candidate drugs for multiple program objectives for neurodegenerative diseases and cancerMSD will obtain its exclusive global R & D and promotion rights, and be responsible for the clinical development and promotion of research therapySkyhawk will receive upfront payments, follow-up payments based on future milestones, and a share of product sales< br / > it is worth mentioning that skyhawk also announced to expand the cooperation agreement with Bojian on the same dayUnder the agreement, Bojian will acquire exclusive global R & D rights beyond its original cooperative research stage, and candidate drugs can be used to treat multiple sclerosis (MS), SMA and other neurological diseases< br / > "MSD has been committed to the research of challenging diseases and the development of new treatment schemes for patients," said Drbill Haney, co-founder and CEO of skyhawk"We are looking forward to using skystar technology platform to screen and promote the research and development of new type candidate drugs for MSD and solve the unmet needs of patients." < br / > DrDean yLi, senior vice president of discovery and translational medicine, moshadong research laboratory, also said that RNA splicing and modification technology has achieved the previously considered impossible goal, and they also look forward to exploring the potential of this new mode of action with skyhawk< br / > References: < br / > [1] skyhawk therapeutics announcements collaboration agreement with Merck to discover and develop new small molecules that modulate RNA spreadingRetrieved July 9, 2019, from < br / > [2] skyhawk therapeutics announcements expansion of collaboration agreement with BiogenRetrieved July 9, 2019, from[3] SkyhawkRetrieved July 9, 2019, from
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.